GlassScriptPhysician profile
David Alan Rizzieri
NPI 1043346877
$713,514.54
in general payments reported to CMS, 2019-2025
37 companies · $633 in 2025
The $633 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200K · 2020: $209K · 2021: $191K · 2022: $107K · 2023: $5,405 · 2024: $651 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,305 · Food and Beverage: $1,709 · Consulting Fee: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,305.00 |
| Food and Beverage | $1,708.64 |
| Consulting Fee | $675.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $303,809.36 | 2019-2024 | Monjuvi, Jakafi |
| Kite Pharma, INC. | $109,368.05 | 2020-2023 | Yescarta |
| Stemline Therapeutics INC. | $79,863.25 | 2019-2022 | |
| Seagen INC. | $40,009.66 | 2019-2022 | |
| Genzyme Corporation | $39,849.67 | 2019-2025 | |
| Gilead Sciences, INC. | $31,330.73 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $28,268.47 | 2019-2023 | |
| Astellas Pharma US INC | $14,356.87 | 2019-2025 | Padcev |
| Aurobindo Pharma USA, INC. | $14,064.23 | 2019-2020 | |
| Pfizer INC. | $11,457.63 | 2019-2024 | |
| Agios Pharmaceuticals, INC. | $10,444.22 | 2019 | |
| Spectrum Pharmaceuticals INC. | $7,760.71 | 2019 | |
| Celgene Corporation | $6,702.53 | 2019-2025 | Reblozyl |
| Abbvie INC. | $6,432.46 | 2022-2023 | |
| Karyopharm Therapeutics INC. | $2,063.41 | 2020-2025 | Xpovio |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kadmon Pharmaceuticals LLC | $1,635.10 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,125.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $1,085.15 | 2019-2024 | |
| Acceleron Pharma, INC. | $845.00 | 2021 | |
| Epizyme, INC. | $675.00 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $600.00 | 2019 | |
| Amgen INC. | $550.00 | 2019 | |
| Glaxosmithkline, LLC. | $401.85 | 2021-2022 | |
| Genentech USA, INC. | $310.18 | 2021-2025 | Lunsumio, Columvi, Polivy |
| Genentech, INC. | $149.78 | 2022 | |
| Celularity INC. | $111.18 | 2022 | |
| Intuitive Surgical, INC. | $74.53 | 2023 | Da Vinci Surgical System |
| Takeda Pharmaceuticals U.S.A., INC. | $64.58 | 2025 | Iclusig, Ninlaro |
| Medtronic, INC. | $62.70 | 2022 | |
| Aveo Pharmaceuticals, INC. | $25.77 | 2025 | |
| Eisai INC. | $17.47 | 2025 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rizzieri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.